Alendronate treatment in patients with osteoarthritis of the hip associated with osteoporosis - Alendronate treatment in patients with hip osteoarthritis

Osaka Osteo-Arthritis Forum (OAF)0 个研究点目标入组 210 人开始时间: 2008年9月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patient who has willing to receive surgery of the hip, or who is scheduled to receive surgery of the hip, at the entry of the study 2) Patient who has willing to bear a child or who is a nursing mother 3) Patient who has serious renal disorder 4) Patient who has experiences of receiving bisphosphonate treatment within 6 months at inclusion of the study 5) Patient who has experiences of receiving drugs having influence on bone remodeling rwithin 8 weeks at inclusion of the study (Vitamin D, Calcitonin, Ipriflavone, Vitamin K, Steroid) 6) Patients with primary or secondary hyperparathyroidism, or with rheumatic arthritis 7) Patients with upper gastrointestinal disorders 8) Patients who is diagnosed as contraindication of alendronate treatements

发起方

Osaka Osteo-Arthritis Forum (OAF)